KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Intangibles: 2018-2024

Historic Intangibles for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Dec 2024 value amounting to $4.4 million.

  • Aurinia Pharmaceuticals' Intangibles fell 13.48% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 13.48%. This contributed to the annual value of $4.4 million for FY2024, which is 12.50% down from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Intangibles of $4.4 million as of FY2024, which was down 12.50% from $5.0 million recorded in FY2023.
  • In the past 5 years, Aurinia Pharmaceuticals' Intangibles registered a high of $9.3 million during FY2020, and its lowest value of $4.4 million during FY2024.
  • Moreover, its 3-year median value for Intangibles was $5.0 million (2023), whereas its average is $5.3 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Intangibles grew by 5.30% in 2020, and later declined by 23.55% in 2022.
  • Over the past 5 years, Aurinia Pharmaceuticals' Intangibles (Yearly) stood at $9.3 million in 2020, then declined by 9.94% to $8.4 million in 2021, then declined by 23.55% to $6.4 million in 2022, then declined by 22.54% to $5.0 million in 2023, then declined by 12.50% to $4.4 million in 2024.